Cost of sale increased significantly more than revenue growth which isn't a good thing for growth companies
HIV sales seem to grow quite slowly with an average price of $3.08... how much does it cost to make it? Doesn't seem like a high-margin product.
OEM basically 0, don't seem to get more until Febridx gets approved.
COVID testing is the only thing keeping the company alive at the moment. However, with tons of competition and average product, will it bring revenues the market expects?
Cost of sale increased significantly more than revenue growth...
Add AT1 (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
3.1¢ |
Change
0.001(3.33%) |
Mkt cap ! $19.81M | |||
| Open | High | Low | Value | Volume |
| 3.0¢ | 3.1¢ | 2.9¢ | $4.745K | 159.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 123968 | 3.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 3.1¢ | 53324 | 2 |
View Market Depth
| Last trade - 16.10pm 03/05/2024 (20 minute delay) ? |
|
|||||
|
Last
3.1¢ |
Change
0.001 ( 3.33 %) |
||||
| Open | High | Low | Volume | ||
| 3.0¢ | 3.1¢ | 2.9¢ | 32795 | ||
| Last updated 15.59pm 03/05/2024 ? | |||||
| AT1 (ASX) Chart |